TauRx analyzed the relationship between the treatment doses, blood levels and pharmacological activity of the drug on the brain in more than 1,000 patients with mild-to-moderate Alzheimer’s disease as part of two Phase III global clinical trials.

Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community, which includes Delaware, Maryland, Virginia and Washington, D.C.

Researchers found that the treatment delayed the development of ALS symptoms in the mice with the ALS mutations.

Based on research done by the MSL Society, the MSL role could grow by 20% in the next 1-2 years and increase by upwards of 35% in Asia and South America. We spoke with an expert to find out more about this innovative position.

5 - 7 November 2019, Frankfurt, Germany.
CPhI Worldwide closed its doors on its landmark 30th edition at the Messe Frankfurt, with pre-audit figures showcasing a record total attendance of 48,961 - 84% of which were international. This year's event saw a number of key indicators pointing to a strong year ahead for pharma in 2020. CPhI Worldwide is widely recognised as a barometer of pharma's overall health - with the addition of

15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

Ted W. Love, president and chief executive officer of GBT, called the approval of Oxbryta a major milestone for the company and for patients with sickle cell disease.

The trial studied the efficacy and safety of adjunctive pimavanserin dosages in patients with predominantly negative symptoms of schizophrenia who had adequate control of positive symptoms with their current antipsychotic treatment.

This article offers a basic roadmap for getting started writing your cover letter for a research scientist job.

Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors. The early thinking on biotech is yes.

The so-called “heart-in-a-jar” will be created from human stem cells and designed to reproduce key phenotypic characteristics of heart failure.

Imagine if an ultrasound could be used as a quantitative tool to measure fat in the liver and detect non-alcoholic fatty liver disease. What seems imaginative is close to becoming reality at Endra Life Sciences.

Could fungi become sources for new drugs to treat a myriad of diseases and disorders? Researchers at the Hubrecht Institute in the Netherlands aim to find out.

If you run a team, you know the power of motivation. Yes, you likely hired people who are very self-motivated and want to succeed for their own satisfaction, but don’t discount what a little appreciation can do to boost someone up.

With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.

The company’s shares exploded 300% in after-hours trading yesterday at the news, giving the company a market value of $469.6 million.

Today, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

"Today's approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who live with this debilitating blood disorder," said Acting FDA Commissioner Adm. Brett P. Giroir, M.D.

U.S. Medicare patients with multiple sclerosis often pay, on average, nearly $7,000 out of pocket to treat their condition each year. And, even though drug companies have provided no new treatment breakthroughs, the price of these disease-modifying medications is rising by 10% to 15% each year for the past decade.

This smooth 24 hours of preparation for your job interview should ensure a long run when you get that job offer.

Effective treatments for diabetes are becoming more and necessary. The past few years have demonstrated productive strides in drug therapies, such as following medications.